MISSION BIOCAPITAL
MISSION BIOCAPITAL is a Pre-seed, Seed and Series A fund in the US and Europe writing $10M–$50M checks into Healthcare, therapeutics, diagnostics, medical-devices, drug-delivery, life-sciences, laboratory-tools and biopharma.
- Stages
- Pre-seed, Seed, Series A
- Sectors
- Healthcare, therapeutics, diagnostics, medical-devices, drug-delivery, life-sciences, laboratory-tools, biopharma
- Check size
- $10M–$50M
- Invests in
- US-wide, Europe
- Actively investing
- Yes
- Founded
- 2009
- Assets under management
- $1.8B+
Thesis
Mission BioCapital is a venture capital firm founded in 2009, specializing in early-stage investments within the life sciences sector. With offices in Cambridge, MA, and San Francisco, CA, the firm focuses on novel therapeutics but also invests in diagnostics, medical devices, laboratory tools, and drug delivery solutions. They actively engage in company creation by collaborating with researchers and entrepreneurs to launch ventures based on innovative technologies. Their support extends beyond capital to include shared lab space, strategic partnerships, and mentorship. Mission BioCapital invests across pre-seed, seed, and Series A stages, with a geographic scope covering the United States and Europe. The firm announced its fifth fund, Mission BioCapital V LP, with $275 million in November 2021, bringing its total AUM to over $1.8 billion. Fund VI closed on $143.75 million in November 2025. Typical deal ranges are between $10 million and $50 million, with an average round size of $40 million.
Common questions
Does MISSION BIOCAPITAL invest at the Pre-seed stage?
Yes. MISSION BIOCAPITAL lists Pre-seed, Seed and Series A among the stages it invests in.
What check size does MISSION BIOCAPITAL write?
MISSION BIOCAPITAL writes $10M–$50M checks.
Where does MISSION BIOCAPITAL invest?
MISSION BIOCAPITAL invests in the US and Europe.